ABSTRACT
OBJECTIVES: Topical treatment is first choice in the treatment of uncomplicated chronic otitis media. It was intended to assess auditory and histopathological safety of ototopical use of mercurochrome solution in rats with induced tympanic membrane perforation. MATERIALS AND METHODS: The study was conducted on 21 female Wistar-Albino rats which were randomly assigned into 3 groups. In all rats, perforation was performed at right tympanic membrane. Distortion product otoacoustic emissions (DPOAEs) measurements were performed at frequencies of 2000, 3000 and 4000 Hz (with L1/L2: 70 /70 dB at 2f1-f2 frequency; f2/f1 ratio: 1:22) before recovery from anesthesia and signal-to-noise ratio (SNR) were recorded. Normal saline, 2% mercurochrome and gentamicin were given to group 1, 2 and 3 twice daily over a week, respectively. Rats were sacrificed after DPOAE measurements on day 14. Right temporal bone specimens were examined under light microscope after processing. RESULTS: Based on DPOAE results, there was no significant difference among groups before treatment. On day 14, significant differences were found in DPOAE measurements at 3000 and 4000 Hz, and in mean SNR values in 2% mercurochrome and gentamicin groups when compared to normal saline group while no significant difference was detected at 2000 Hz among groups. In addition, significant degeneration was detected in Corti organs, spiral ganglions and stria vascularis in groups 2 and 3. CONCLUSION: In this study, it was observed that mercurochrome use in external otitis and otitis media with tympanic membrane perforation could cause ototoxicity and concluded that the solution should be used cautiously.
Subject(s)
Hearing/drug effects , Merbromin/adverse effects , Ototoxicity/complications , Tympanic Membrane Perforation/drug therapy , Tympanic Membrane/drug effects , Administration, Topical , Animals , Anti-Bacterial Agents/administration & dosage , Cochlea/drug effects , Cochlea/ultrastructure , Female , Gentamicins/administration & dosage , Merbromin/administration & dosage , Merbromin/therapeutic use , Merbromin/toxicity , Organomercury Compounds/therapeutic use , Otitis Externa/drug therapy , Otitis Media/drug therapy , Perceptual Distortion/drug effects , Rats , Rats, Wistar , Signal-To-Noise RatioSubject(s)
Gentamicins/blood , Mercury/blood , Vancomycin/blood , Fluorescence Polarization , Humans , Infant , Merbromin/therapeutic use , Merbromin/toxicityABSTRACT
Debe utilizarse la denominación original de Merbromin, para designar a este antiséptico local, o en su defecto la de Mercurocromo, por inducir ésta a una concepción equívoca de la composición del producto, integrado entre otros por lo iones bromo y mercurio, nunca por el cromo que no forma parte de su fórmula de constitución. Los casos expuestos no son en nuestro criterio otra cosa que "casos particulares de sensibilización al Mercurio en forma orgánica e inorgánica. El Mercurocromo de acuerdo con la patogenia de la sensibilización que se pone en juego, da lugar a manifestaciones locales y sistemáticas bien caracterizadas, a las que nos hemos referido en el curso de este trabajo(AU)